ABTC Active Protocols

Recurrent Disease

 

Mibefradil (ABTC1101):

A Phase I Open Label Safety Study to Evaluate the Pharmacokinetic Profile and Tolerance of Mibefradil Dose Finding in Subjects with Recurrant High-Grade Glioma Undergoing Standard, Repeated Temozolomide Treatment.

 

MLN0128 (ABTC1301):

A Pilot Study of MLN0128 in Preoperative Recurrent Glioblastoma (GBM) Patients
 

 

Newly-Diagnosed Disease

 

MK-1775 (ABTC1202):

A Phase I Study of MK-1775 with Radiation and Temozolomide in Patients with Newly Diagnosed Glioblastoma and Evaluation of Intratumoral Drug Distribution in Patients with Recurrent Glioblastoma.